Project Grant HT94252510154
Award Date
6/1/25
Completion Date
5/31/29
Dollars Obligated
$2.9M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
The Defense Health Agency awarded The Trustees of the University of Pennsylvania $750,484 under the Military Medical Research and Development program (CFDA 12.420) for the period of June 1, 2023 through May 31, 2025. The project aims to identify plasma biomarkers in amyotrophic lateral sclerosis (ALS) and related disorders that can classify clinical subtypes and provide prognostic information. Specifically, the University of Pennsylvania will evaluate plasma P-tau181 and neurofilament light...
The federal Project Grant award of $2,311,734.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the "Development and Evaluation of a Care Pathway for Evaluation and Management of the Respiratory Syndromes of Amyotrophic Lateral Sclerosis (ALS) [CAPRESA]" at the Denver Research Institute (DRI). This non-profit research organization will conduct advanced medical research, data analysis, and clinical studies...
This $894,330.00 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program supports advanced biomedical research to transform healthcare for military service members and the broader public. The grant is funding research at the University of Miami's Office of Research Administration - School of Medicine Division to investigate "Targeting Axonal Regeneration Pathways as a Therapeutic Approach to ALS." The...
The Defense Health Agency awarded Thomas Jefferson University a $779,200 project grant under the Military Medical Research and Development program (CFDA 12.420) to conduct senotherapy research for amyotrophic lateral sclerosis (ALS) from April 1, 2023 through March 31, 2025. The grant will support basic, applied, and advanced biomedical research investigating medical solutions for ALS, consistent with the program's goals of transforming military and public health care through innovative...
The Trustees of the University of Pennsylvania will receive $975,000 through a three-year Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will support lung cancer research from July 1, 2023 to June 30, 2026. Through this funding, the University and its Clinical Practices will conduct biomedical research to transform service member healthcare and investigate medical solutions applicable to battlefield medicine....
The University of Pennsylvania's Clinical Practices is the recipient of a $861,250 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 30, 2024, supports the advancement of mechanistic understanding of autoimmunity in aplastic anemia through HLA allele specificity research. The project aims to provide critical insights that could lead to improved treatments for this medical condition, with a...
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
This $1,181,251.00 federal Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) grant program. The grant supports research to develop neuronal exosome-based biomarkers for amyotrophic lateral sclerosis (ALS) diagnosis and disease progression monitoring. The prime awardee is the University of California, Los Angeles (UCLA), which will leverage its research expertise and facilities to conduct this 3-year study. The key...
This Project Grant award of $2,163,115.00, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by Pathmaker Neurosystems Inc. to develop a noninvasive neuromodulation approach to slow the progression of amyotrophic lateral sclerosis (ALS) by suppressing neuronal hyperexcitability. The research, taking place in Boston, MA, aims to explore this innovative therapeutic method over the 2-year performance period...
This federal Project Grant award in the amount of $2,180,261.00 was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Projenx Inc., a small disadvantaged business located in New York, NY. The purpose of this 2-year grant, awarded on April 1, 2025, is to conduct a Phase 1C study of Prosetin, a novel, brain-penetrant MAP4K inhibitor, in participants with amyotrophic lateral sclerosis (ALS). The research aims to advance innovative...